<DOC>
	<DOCNO>NCT00876577</DOCNO>
	<brief_summary>This study local , prospective , open-label , company-sponsored , non interventional , multi-center study . Patients document must suffer acute exacerbation chronic bronchitis take least one dose Moxifloxacin injection.The primary objective obtain clinical effectiveness safety data Moxifloxacin injection treatment acute exacerbation chronic bronchitis patient Moxifloxacin routinely prescribe . The secondary objective find possible correlation risk factor ( sex , smoking , number previous exacerbation , etc ) AECB , different treatment effectiveness accord Anthonisen classification . This study also collect data pathogen sputum culture defervescence time Moxifloxacin injection treat Acute Exacerbations Chronic Bronchitis ( AECB ) .</brief_summary>
	<brief_title>VICTOR - AveloxÂ® Intravenous ( i.v . ) Acute Exacerbations Chronic Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients least 18 year age diagnosis AECB treat Moxifloxacin injection with/without sequential tablet treatment Exclusion criterion must read conjunction local product information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Acute Exacerbations Chronic Bronchitis</keyword>
	<keyword>Avelox</keyword>
	<keyword>Bronchitis</keyword>
</DOC>